High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease

Long term follow-up in 128 patients

Philip Jay Bierman, R. G. Bagin, S. Jagannath, Julie Marie Vose, G. Spitzer, A. Kessinger, K. A. Dicke, James Olen Armitage

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Background: There is little long term follow-up information after autologous transplantation for Hodgkin's disease. We evaluated the influence of various prognostic factors and examined the outcome in 128 such patients. Patients and methods: Patients received high dose cyclo-phosphamide, carmustine, and etoposide followed by autologous hematopoietic rescue. Results: Patients have been observed between 50-130 months (median 77 months) following transplantation. Overall survival at four years is estimated as 45 percent, and failure-free survival as 25 percent. The best results were seen in patients with a good performance status, who had failed at most one prior chemotherapy regimen. Failure-free survival at four years is estimated as 53 percent for this group. Relapses more than 24 months after transplantation were seen in 11 patients. Five patients developed myelodysplastic syndromes. Three patients became pregnant after the transplant. Conclusions: Prolonged failure-free survival may be observed following high dose chemotherapy and autologous hematopoietic rescue in patients with Hodgkin's disease. Superior results were seen in patients without extensive prior chemotherapy and in those with a good performance status. Late relapses and deaths from secondary myelodysplastic syndromes mandate prolonged follow-up after autologous transplantation for Hodgkin's disease.

Original languageEnglish (US)
Pages (from-to)767-773
Number of pages7
JournalAnnals of Oncology
Volume4
Issue number9
StatePublished - Nov 1 1993

Fingerprint

Hodgkin Disease
Drug Therapy
Survival
Autologous Transplantation
Myelodysplastic Syndromes
Transplantation
Dimethoate
Recurrence
Carmustine
Etoposide
Transplants

Keywords

  • Bone marrow transplantation
  • Hodgkin's disease
  • Late complications
  • Peripheral stem cell transplantation
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease : Long term follow-up in 128 patients. / Bierman, Philip Jay; Bagin, R. G.; Jagannath, S.; Vose, Julie Marie; Spitzer, G.; Kessinger, A.; Dicke, K. A.; Armitage, James Olen.

In: Annals of Oncology, Vol. 4, No. 9, 01.11.1993, p. 767-773.

Research output: Contribution to journalArticle

@article{cdc1f05fafa1464d8cf615503dd4ce04,
title = "High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients",
abstract = "Background: There is little long term follow-up information after autologous transplantation for Hodgkin's disease. We evaluated the influence of various prognostic factors and examined the outcome in 128 such patients. Patients and methods: Patients received high dose cyclo-phosphamide, carmustine, and etoposide followed by autologous hematopoietic rescue. Results: Patients have been observed between 50-130 months (median 77 months) following transplantation. Overall survival at four years is estimated as 45 percent, and failure-free survival as 25 percent. The best results were seen in patients with a good performance status, who had failed at most one prior chemotherapy regimen. Failure-free survival at four years is estimated as 53 percent for this group. Relapses more than 24 months after transplantation were seen in 11 patients. Five patients developed myelodysplastic syndromes. Three patients became pregnant after the transplant. Conclusions: Prolonged failure-free survival may be observed following high dose chemotherapy and autologous hematopoietic rescue in patients with Hodgkin's disease. Superior results were seen in patients without extensive prior chemotherapy and in those with a good performance status. Late relapses and deaths from secondary myelodysplastic syndromes mandate prolonged follow-up after autologous transplantation for Hodgkin's disease.",
keywords = "Bone marrow transplantation, Hodgkin's disease, Late complications, Peripheral stem cell transplantation, Prognostic factors",
author = "Bierman, {Philip Jay} and Bagin, {R. G.} and S. Jagannath and Vose, {Julie Marie} and G. Spitzer and A. Kessinger and Dicke, {K. A.} and Armitage, {James Olen}",
year = "1993",
month = "11",
day = "1",
language = "English (US)",
volume = "4",
pages = "767--773",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease

T2 - Long term follow-up in 128 patients

AU - Bierman, Philip Jay

AU - Bagin, R. G.

AU - Jagannath, S.

AU - Vose, Julie Marie

AU - Spitzer, G.

AU - Kessinger, A.

AU - Dicke, K. A.

AU - Armitage, James Olen

PY - 1993/11/1

Y1 - 1993/11/1

N2 - Background: There is little long term follow-up information after autologous transplantation for Hodgkin's disease. We evaluated the influence of various prognostic factors and examined the outcome in 128 such patients. Patients and methods: Patients received high dose cyclo-phosphamide, carmustine, and etoposide followed by autologous hematopoietic rescue. Results: Patients have been observed between 50-130 months (median 77 months) following transplantation. Overall survival at four years is estimated as 45 percent, and failure-free survival as 25 percent. The best results were seen in patients with a good performance status, who had failed at most one prior chemotherapy regimen. Failure-free survival at four years is estimated as 53 percent for this group. Relapses more than 24 months after transplantation were seen in 11 patients. Five patients developed myelodysplastic syndromes. Three patients became pregnant after the transplant. Conclusions: Prolonged failure-free survival may be observed following high dose chemotherapy and autologous hematopoietic rescue in patients with Hodgkin's disease. Superior results were seen in patients without extensive prior chemotherapy and in those with a good performance status. Late relapses and deaths from secondary myelodysplastic syndromes mandate prolonged follow-up after autologous transplantation for Hodgkin's disease.

AB - Background: There is little long term follow-up information after autologous transplantation for Hodgkin's disease. We evaluated the influence of various prognostic factors and examined the outcome in 128 such patients. Patients and methods: Patients received high dose cyclo-phosphamide, carmustine, and etoposide followed by autologous hematopoietic rescue. Results: Patients have been observed between 50-130 months (median 77 months) following transplantation. Overall survival at four years is estimated as 45 percent, and failure-free survival as 25 percent. The best results were seen in patients with a good performance status, who had failed at most one prior chemotherapy regimen. Failure-free survival at four years is estimated as 53 percent for this group. Relapses more than 24 months after transplantation were seen in 11 patients. Five patients developed myelodysplastic syndromes. Three patients became pregnant after the transplant. Conclusions: Prolonged failure-free survival may be observed following high dose chemotherapy and autologous hematopoietic rescue in patients with Hodgkin's disease. Superior results were seen in patients without extensive prior chemotherapy and in those with a good performance status. Late relapses and deaths from secondary myelodysplastic syndromes mandate prolonged follow-up after autologous transplantation for Hodgkin's disease.

KW - Bone marrow transplantation

KW - Hodgkin's disease

KW - Late complications

KW - Peripheral stem cell transplantation

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0027374883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027374883&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 767

EP - 773

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -